is a reporter who writes about tech, money, and human behavior. She joined The Verge in 2014 as science editor. Previously, she was a reporter at Bloomberg. I admit, this is an innovation I did not see coming: Silicon Valley has invented the philosophical zombie from the classic thought experiment “lol how crazy would it be if there were a philosophical zombie.” Until recently, the philosophical z...
is a reporter who writes about tech, money, and human behavior. She joined The Verge in 2014 as science editor. Previously, she was a reporter at Bloomberg. I admit, this is an innovation I did not see coming: Silicon Valley has invented the philosophical zombie from the classic thought experiment “lol how crazy would it be if there were a philosophical zombie.” Until recently, the philosophical zombie was a concept closely associated with Australian philosopher David Chalmers, who defines it as “someone or something physically identical to me (or to any other conscious being), but lacking conscious experiences altogether.” Chalmers’ zombie twin is identical to him functionally and psychologically — except that he feels nothing. This is different from a Hollywood zombie, which has “little capacity for introspection and lack[s] a refined ability to voluntarily control behavior.” So okay, Marc Andreessen is even shallower than our standard philosophical zombie — but still, I think there is a strong case he should be hunted and captured by the Stanford philosophy department so they can try their thought experiments out on him in real life. (Humanely, of course.) But I think for all of us who are interested in consciousness, Andreessen is certainly a specimen. For those of you who are not as internet-poisoned as I am, let me recap: A video of Andreessen on David Senra’s podcast — podcasts being Andreessen’s favored form of self-disclosure — has been making the rounds. In the video, Andreessen cheerfully says he has “zero” levels of introspection — “as little as possible.” This is a positive for entrepreneurs, we are told. “And you know, if you go back 400 years ago, it never would have occurred to anybody to be introspective,” Andreessen says, thus setting himself up for thunderous dunking. I could point to the many ancient traditions of introspection (set out variously in the Bhagavad Gita, Plato, or Psalm 119) or note that his comments about a “guilt-based whammy” tha...
FedEx press release ( FDX ): Q3 Non-GAAP EPS of $5.25 beats by $1.12 . Revenue of $24B (+8.1% Y/Y) beats by $520M . Outlook FedEx is unable to forecast the fiscal 2026 mark-to-market (“MTM”) retirement plans accounting adjustments. As a result, FedEx is unable to provide a fiscal 2026 earnings per share (“EPS”) or effective tax rate (“ETR”) outlook on a GAAP basis and is relying on the exemption p...
FedEx press release ( FDX ): Q3 Non-GAAP EPS of $5.25 beats by $1.12 . Revenue of $24B (+8.1% Y/Y) beats by $520M . Outlook FedEx is unable to forecast the fiscal 2026 mark-to-market (“MTM”) retirement plans accounting adjustments. As a result, FedEx is unable to provide a fiscal 2026 earnings per share (“EPS”) or effective tax rate (“ETR”) outlook on a GAAP basis and is relying on the exemption provided by the Securities and Exchange Commission (“SEC”). It is reasonably possible that the fiscal 2026 MTM retirement plans accounting adjustments could have a material effect on fiscal 2026 consolidated financial results and ETR. FedEx is revising its fiscal 2026 outlook, and now expects: A 6.0% to 6.5% revenue growth rate year over year, compared to the prior forecast of 5% to 6% growth; Diluted earnings per share of $16.05 to $16.85 before the MTM retirement plans accounting adjustments compared to the prior forecast of $14.80 to $16.00, and $19.30 to $20.10 after also excluding costs related to the planned spin-off of FedEx Freight, business optimization initiatives, the planned change in the company's fiscal year end, and an international regulatory matter, compared to the prior forecast of $17.80 to $19.00; Permanent cost reductions of more than $1 billion in transformation-related savings from structural cost reductions and the advancement of Network 2.0, compared to the prior forecast of $1 billion; An ETR of approximately 24% prior to the MTM retirement plans accounting adjustments, compared to the prior forecast of approximately 25%; Pension contributions of $275 million, compared to the prior forecast of up to $275 million; and Capital spending of no more than $4.1 billion, with a priority on investments in network optimization and efficiency improvement, including fleet and facility modernization and automation, compared to the December forecast of $4.5 billion. Shares +1.65% AH. More on FedEx FedEx Corporation: Its Valuation Has Already Traveled Quite Too Fa...
Goldman Sachs is warning investors to brace for a possible stock correction that won't necessarily be buffered by bonds. While the markets started the year risk on, concerns about the spike in oil prices, Iran war and artificial-intelligence disruption have dragged equities down. The Dow Jones Industrial Average , S & P 500 and Nasdaq Composite are all in the red so far in 2026. That sell-off coul...
Goldman Sachs is warning investors to brace for a possible stock correction that won't necessarily be buffered by bonds. While the markets started the year risk on, concerns about the spike in oil prices, Iran war and artificial-intelligence disruption have dragged equities down. The Dow Jones Industrial Average , S & P 500 and Nasdaq Composite are all in the red so far in 2026. That sell-off could deepen, Christian Mueller-Glissmann, head of Goldman's asset allocation research, said in a note Thursday. "While geopolitical shocks and their market impact are difficult to time, we think equities have not priced in enough risk premium for the risk of a more lasting shock — based on the disruptions so far our economists have already reflected a worsening," he wrote. In addition, the buffer from bonds, which traditionally have served as a ballast in portfolios, will be limited, he said. Therefore, "the risk of a larger 60/40 portfolio drawdown … has increased," Mueller-Glissmann cautioned. Shifting portfolios Goldman has shifted more defensively in its asset allocation for the next three months and is overweight cash, underweight on credit and neutral on equities, bonds and commodities. For allocations over the next six months, it bumps up its risk to overweight equities and moves cash to neutral. The firm's long-term world portfolio proxy , which spans global equities and bonds, as well as gold, has lost about 4% since the start of the Iran war — a "small drawdown in a long-run context," Mueller-Glissmann said. However, while the risk of a sustained, large 60/40 loss is still limited, investors should consider mitigating continued stagflationary risks by beefing up their multi-asset portfolios, he said. "[W]e believe investors can look at a combination of up-in-quality trades in equity/credit/FX, allocations to alternatives, dynamic risk allocation, and option overlays in equities and across assets," Mueller-Glissmann said. Since the start of the year, exposure to defen...
Global military conflicts are prompting some nations to take preventive measures, boosting defense spending today to potentially ward off aggression. Greece is among the countries taking pre-emptive steps. Earlier this week, a parliamentary committee there approved a spending package of up to $36 billion over a decade to bolster its air defense system, including the "Achilles Shield," which is aki...
Global military conflicts are prompting some nations to take preventive measures, boosting defense spending today to potentially ward off aggression. Greece is among the countries taking pre-emptive steps. Earlier this week, a parliamentary committee there approved a spending package of up to $36 billion over a decade to bolster its air defense system, including the "Achilles Shield," which is akin to Israel's "Iron Dome." The objective is to be prepared if the relationship with neighboring Turkey, which is described by some as "unneighborly" and tense, turns sour. Some investors may be pondering if Greece's pledge to increase air defense spending will help already high-flying shares of Lockheed Martin (LMT 1.09%) gain more altitude, but the devil is in the details. Greek spending helps, but it's not a near-term jolt Over the five days ending March 18, a period that included Greek news, shares of Lockheed dipped 2.52%. Sure, some of that has to do with weakness in the broader market, and that dip might be a case of some profit-taking in a stock that's up nearly 33% year to date. It may also be a result of markets saying Greece's upped spending pledge isn't going to be a near-term tailwind to Lockheed's earnings per share. Sure, that may be disappointing to investors who know the history between this company and Greece, which spans 75 years and includes famed aircraft such as the F-16 and F-35, among others, but context matters. Lockheed Martin is a $146.41 billion company. Hence, a contract worth $36 billion spanning a decade isn't a game changer in the near term, even though it's additive to the longer-term investment thesis. Additional context can ease some of the aforementioned disappointment because even if Greece spends the full $36 billion through 2035, not all of that capital will go to Lockheed. At least $3.5 billion is being directed to a pair of Israeli companies. Expand NYSE : LMT Lockheed Martin Today's Change ( -1.09 %) $ -6.97 Current Price $ 635.30 Ke...
Key Points Lockheed Martin is a long-standing supplier to Greece. The country will spend up to $36 billion bolstering its “Achilles Shield” air defense system. That spending package includes orders for Lockheed Martin equipment, but it doesn’t really move the needle for the stock. 10 stocks we like better than Lockheed Martin › Global military conflicts are prompting some nations to take preventiv...
Key Points Lockheed Martin is a long-standing supplier to Greece. The country will spend up to $36 billion bolstering its “Achilles Shield” air defense system. That spending package includes orders for Lockheed Martin equipment, but it doesn’t really move the needle for the stock. 10 stocks we like better than Lockheed Martin › Global military conflicts are prompting some nations to take preventive measures, boosting defense spending today to potentially ward off aggression. Greece is among the countries taking pre-emptive steps. Earlier this week, a parliamentary committee there approved a spending package of up to $36 billion over a decade to bolster its air defense system, including the "Achilles Shield," which is akin to Israel's "Iron Dome." The objective is to be prepared if the relationship with neighboring Turkey, which is described by some as "unneighborly" and tense, turns sour. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Some investors may be pondering if Greece's pledge to increase air defense spending will help already high-flying shares of Lockheed Martin (NYSE: LMT) gain more altitude, but the devil is in the details. Greek spending helps, but it's not a near-term jolt Over the five days ending March 18, a period that included Greek news, shares of Lockheed dipped 2.52%. Sure, some of that has to do with weakness in the broader market, and that dip might be a case of some profit-taking in a stock that's up nearly 33% year to date. It may also be a result of markets saying Greece's upped spending pledge isn't going to be a near-term tailwind to Lockheed's earnings per share. Sure, that may be disappointing to investors who know the history between this company and Greece, which spans 75 years and includes famed aircraft such as the F-16 and F-35, among others, but context matters...
If you're a higher earner, you may be in the habit of regularly funding an IRA or 401(k). Not only can contributions to these retirement plans give you a nice tax break, but they could also help you enjoy a very comfortable lifestyle down the line. You might assume that there's no need to bother with a health savings account, or HSA, if you earn a higher salary. If you make enough money, you can j...
If you're a higher earner, you may be in the habit of regularly funding an IRA or 401(k). Not only can contributions to these retirement plans give you a nice tax break, but they could also help you enjoy a very comfortable lifestyle down the line. You might assume that there's no need to bother with a health savings account, or HSA, if you earn a higher salary. If you make enough money, you can just pay for near-term and future medical bills as they arise. But actually, as a higher earner, you may be in a unique position to benefit the most from an HSA. So it pays to open one if you're enrolled in a high-deductible health insurance plan that's HSA-eligible. Why higher earners in particular can benefit from an HSA One reason HSAs are so powerful for higher earners is their tax treatment. With an HSA, you get three distinct and important tax breaks: Contributions are made with pre-tax dollars Investment gains are tax-free Withdrawals are tax-free when used for qualifying healthcare expenses Let's unpack each of these. If you're a higher earner, you may be in a higher tax bracket. If so, every dollar you contribute to an HSA shields some income from the IRS. Secondly, if you have a high enough income to cover your near-term medical bills, you can potentially leave your HSA alone so your invested money grows tax-free over many years. That could, depending on your situation, leave you with a very large pool of money to pay for healthcare costs in retirement, when those bills might rise and when you may want to use your IRA or 401(k) to pay for other things. Finally, as a high earner, it may not make sense for you to contribute to a Roth IRA or 401(k), as you may need the immediate tax break that comes with funding a traditional retirement account. If so, you could be looking at a lot of taxable income in retirement. So being able to withdraw from an HSA tax-free at that stage of life could help reduce your total tax bill. Don't write off an HSA You might think you don't...
Key Points If you earn a nice income, you might assume you don't need an HSA. As a higher earner, you're actually in a unique position to make the most of one. That money could potentially grow into a large sum, leaving you with a nice pool of funds for retierment. The $23,760 Social Security bonus most retirees completely overlook › If you're a higher earner, you may be in the habit of regularly ...
Key Points If you earn a nice income, you might assume you don't need an HSA. As a higher earner, you're actually in a unique position to make the most of one. That money could potentially grow into a large sum, leaving you with a nice pool of funds for retierment. The $23,760 Social Security bonus most retirees completely overlook › If you're a higher earner, you may be in the habit of regularly funding an IRA or 401(k). Not only can contributions to these retirement plans give you a nice tax break, but they could also help you enjoy a very comfortable lifestyle down the line. You might assume that there's no need to bother with a health savings account, or HSA, if you earn a higher salary. If you make enough money, you can just pay for near-term and future medical bills as they arise. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » But actually, as a higher earner, you may be in a unique position to benefit the most from an HSA. So it pays to open one if you're enrolled in a high-deductible health insurance plan that's HSA-eligible. Why higher earners in particular can benefit from an HSA One reason HSAs are so powerful for higher earners is their tax treatment. With an HSA, you get three distinct and important tax breaks: Contributions are made with pre-tax dollars Investment gains are tax-free Withdrawals are tax-free when used for qualifying healthcare expenses Let's unpack each of these. If you're a higher earner, you may be in a higher tax bracket. If so, every dollar you contribute to an HSA shields some income from the IRS. Secondly, if you have a high enough income to cover your near-term medical bills, you can potentially leave your HSA alone so your invested money grows tax-free over many years. That could, depending on your situation, leave you with a very large pool of money to pay f...
A bank retreat from private credit piles pressure on business development companies already reeling from a wave of redemptions, according to SLR Investment Corp. “You’re starting to see banks get nervous and start to pull back,” the BDC’s co-Chief Executive Officer Michael Gross tells Bloomberg News’ James Crombie and Bloomberg Intelligence’s Arnold Kakuda in this episode of the Credit Edge podcas...
A bank retreat from private credit piles pressure on business development companies already reeling from a wave of redemptions, according to SLR Investment Corp. “You’re starting to see banks get nervous and start to pull back,” the BDC’s co-Chief Executive Officer Michael Gross tells Bloomberg News’ James Crombie and Bloomberg Intelligence’s Arnold Kakuda in this episode of the Credit Edge podcast. “It’s going to increase people’s cost of capital, which will make it harder for people to invest
Relmada Therapeutics press release ( RLMD ): Q4 GAAP EPS of -$0.27 misses by $0.13 . Research and development expense for the three months ended December 31, 2025, totaled $8.1 million, compared to $11.0 million for the three months ended December 31, 2024, a decrease of $2.9 million. General and administrative expense for the three months ended December 31, 2025, totaled $12.3 million compared to...
Relmada Therapeutics press release ( RLMD ): Q4 GAAP EPS of -$0.27 misses by $0.13 . Research and development expense for the three months ended December 31, 2025, totaled $8.1 million, compared to $11.0 million for the three months ended December 31, 2024, a decrease of $2.9 million. General and administrative expense for the three months ended December 31, 2025, totaled $12.3 million compared to $8.1 million for the three months ended December 31, 2024, an increase of approximately $4.2 million. More on Relmada Therapeutics Seeking Alpha’s Quant Rating on Relmada Therapeutics Historical earnings data for Relmada Therapeutics Financial information for Relmada Therapeutics
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Gemini Space Station, Inc. (“Gemini”) (NASDAQ: GEMI) today reported its fourth quarter and full year 2025 financial results in a shareholder letter and earnings presentation which can be found on its Investor Relations website at https://investors.gemini.com . Management will host a conference call at 8:30 am ET tomorrow, March 20, to discuss the result...
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Gemini Space Station, Inc. (“Gemini”) (NASDAQ: GEMI) today reported its fourth quarter and full year 2025 financial results in a shareholder letter and earnings presentation which can be found on its Investor Relations website at https://investors.gemini.com . Management will host a conference call at 8:30 am ET tomorrow, March 20, to discuss the results. The event will be webcast live via our Investor Relations website or via this link . Following the call, a replay and transcript will also be available at https://investors.gemini.com . Channels for Disclosure of Information As a reminder, we announce material information to the public through filings with the Securities and Exchange Commission (SEC), the investor relations page on our website (investors.gemini.com), the blog on our website (www.gemini.com/blog), press releases, public conference calls, public webcasts, our X account (@gemini), and our LinkedIn page. The information disclosed in the foregoing channels could be deemed to be material information. As such, we encourage investors, the media, and others to follow the channels listed above and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which we will announce information will be posted on the investor relations page on our website. About Gemini Gemini (NASDAQ: GEMI) is a global crypto and prediction markets platform founded by Cameron and Tyler Winklevoss in 2014. Gemini offers a wide range of crypto and markets products and services for individuals and institutions. Gemini's simple, reliable, and secure products are built to unlock the next era of financial, creative, and personal freedom. Contact Investors Gemini Investor Relations Email: investors@gemini.com Press Natalie Johnson Email: press@gemini.com
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Baidu has launched DuClaw, a zero deployment AI agent service designed to make advanced AI tools easier to use. The service removes the need for users to handle infrastructure or complex setup, lowering technical barriers to AI agent adoption. DuClaw targets...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Baidu has launched DuClaw, a zero deployment AI agent service designed to make advanced AI tools easier to use. The service removes the need for users to handle infrastructure or complex setup, lowering technical barriers to AI agent adoption. DuClaw targets developers, enterprises and AI enthusiasts who want quicker access to production ready AI agents. Baidu, listed as NasdaqGS:BIDU, is rolling out DuClaw at a time when its share price stands at $121.87. The stock has seen mixed performance, with a 24.1% return over the past year alongside declines of 18.9% year to date and 49.0% over five years. This backdrop gives extra weight to product moves that relate directly to Baidu's role in applied AI. By focusing DuClaw on ease of use and zero deployment, Baidu is aiming at broader adoption of AI agents across different types of users. Readers tracking NasdaqGS:BIDU may want to watch how quickly DuClaw gains traction with developers and enterprises and how that interest translates into real world usage of Baidu's AI stack. Stay updated on the most important news stories for Baidu by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Baidu. NasdaqGS:BIDU Earnings & Revenue Growth as at Mar 2026 1 thing going right for Baidu that this headline doesn't cover. Quick Assessment ✅ Price vs Analyst Target : At US$121.87, Baidu trades about 31% below the US$176.22 analyst target. ⚖️ Simply Wall St Valuation : Shares are described as trading close to estimated fair value. ❌ Recent Momentum: The 30 day return is about an 11% decline. To decide whether to buy, sell or hold Baidu, you can review the Simply Wall St company report for the latest analysis of Baidu's fair value. Key Considerations 📊 DuClaw pushes Baidu further into applied AI, which may influence how much weight you pla...
May NY world sugar #11 (SBK26) on Thursday closed up +0.57 (+3.85%), and May London ICE white sugar #5 (SWK26) closed up +13.80 (+3.16%). Sugar prices added to this week's sharp rally on Thursday, climbing to 5-month highs. Soaring gasoline prices are boosting ethanol prices and are bullish for sugar. Gasoline (RBJ26) rallied to a 3.5-year high on Thursday, which may encourage the world's sugar mi...
May NY world sugar #11 (SBK26) on Thursday closed up +0.57 (+3.85%), and May London ICE white sugar #5 (SWK26) closed up +13.80 (+3.16%). Sugar prices added to this week's sharp rally on Thursday, climbing to 5-month highs. Soaring gasoline prices are boosting ethanol prices and are bullish for sugar. Gasoline (RBJ26) rallied to a 3.5-year high on Thursday, which may encourage the world's sugar mills to increase ethanol production at the expense of sugar. Don’t Miss a Day: Sugar prices are also finding support amid supply disruptions from the closure of the Strait of Hormuz. According to Covrig Analytics, the closure of the strait has curbed approximately 6% of the world's sugar trade, constraining refined sugar output. Earlier this month, sugar prices plunged to 5.25-year nearest-futures lows on concern that a global sugar surplus will persist. On February 11, analysts from sugar trader Czarnikow said they expect a global sugar surplus of 3.4 MMT in the 2026/27 crop year, following an 8.3 MMT surplus in 2025/26. Also, Green Pool Commodity Specialists said on January 29 that they expect a 2.74 MMT global sugar surplus for 2025/26 and a 156,000 MT surplus for 2026/27. Meanwhile, StoneX said February 13 that it expects a global sugar surplus of 2.9 MMT in 2025/26. The International Sugar Organization (ISO) on February 27 forecasted a +1.22 MMT (million metric ton) sugar surplus in 2025-26, following a -3.46 MMT deficit in 2024-25. ISO said the surplus is being driven by increased sugar production in India, Thailand, and Pakistan. ISO is forecasting a +3.0% y/y rise in global sugar production to 181.3 million MMT in 2025-26. Signs of lower sugar output in Brazil are supportive of sugar prices, after Unica on February 18 reported that sugar production in Brazil's Center-South in the second half of January fell by -36% y/y to only 5,000 MT. However, cumulative 2025-26 Center-South sugar output through January rose +0.9% y/y to 40.24 MMT. The Indian Sugar and Bio-energy M...
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Microsoft’s fair value price target has been nudged from US$595.99 to US$594.62, a small reset that keeps the broader long term story largely intact. Analysts linking this move to AI related capital spending, growth assumptions, and recalibrated expectations describe a more balanced mix of e...
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Microsoft’s fair value price target has been nudged from US$595.99 to US$594.62, a small reset that keeps the broader long term story largely intact. Analysts linking this move to AI related capital spending, growth assumptions, and recalibrated expectations describe a more balanced mix of enthusiasm and caution, with some trimming targets while maintaining constructive views. As you read on, you will see how these shifts fit into the evolving Microsoft narrative and what to watch as new research comes out. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Microsoft. What Wall Street Has Been Saying 🐂 Bullish Takeaways Goldman Sachs, HSBC and Barclays highlight Microsoft as a key beneficiary of AI being built into enterprise software, with Goldman calling out AI as a positive tailwind and HSBC arguing that established software platforms are well placed to integrate agents and automation. Several firms, including Wells Fargo, Barclays and Goldman Sachs, continue to frame Microsoft as a core way to get exposure to AI infrastructure and software, pointing to its role across cloud, custom silicon programs and large scale enterprise deployments. Rosenblatt and H.C. Wainwright reference Microsoft as an anchor customer in AI related networking and infrastructure contracts. In their view, this underpins demand signals for selected suppliers and partners tied to Microsoft’s build out. 🐻 Bearish Takeaways Melius Research and Stifel have flagged concerns that some forward estimates for Microsoft, including projections around AI and 2027 earnings, may be too optimistic. This has prompted rating changes and more cautious language on how much is already reflected in valuations. A long list of banks and brokers, among them Goldman Sachs, UBS, JPMorgan, Evercore ISI, BMO Capital and others, have trimmed Micros...
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Microsoft’s fair value price target has been nudged from US$595.99 to US$594.62, a small reset that keeps the broader long term story largely intact. Analysts linking this move to AI related capital spending, growth assumptions, and recalibrated expectations describe a more balanced mix of e...
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Microsoft’s fair value price target has been nudged from US$595.99 to US$594.62, a small reset that keeps the broader long term story largely intact. Analysts linking this move to AI related capital spending, growth assumptions, and recalibrated expectations describe a more balanced mix of enthusiasm and caution, with some trimming targets while maintaining constructive views. As you read on, you will see how these shifts fit into the evolving Microsoft narrative and what to watch as new research comes out. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Microsoft. What Wall Street Has Been Saying 🐂 Bullish Takeaways Goldman Sachs, HSBC and Barclays highlight Microsoft as a key beneficiary of AI being built into enterprise software, with Goldman calling out AI as a positive tailwind and HSBC arguing that established software platforms are well placed to integrate agents and automation. Several firms, including Wells Fargo, Barclays and Goldman Sachs, continue to frame Microsoft as a core way to get exposure to AI infrastructure and software, pointing to its role across cloud, custom silicon programs and large scale enterprise deployments. Rosenblatt and H.C. Wainwright reference Microsoft as an anchor customer in AI related networking and infrastructure contracts. In their view, this underpins demand signals for selected suppliers and partners tied to Microsoft’s build out. 🐻 Bearish Takeaways Melius Research and Stifel have flagged concerns that some forward estimates for Microsoft, including projections around AI and 2027 earnings, may be too optimistic. This has prompted rating changes and more cautious language on how much is already reflected in valuations. A long list of banks and brokers, among them Goldman Sachs, UBS, JPMorgan, Evercore ISI, BMO Capital and others, have trimmed Micros...
United States Antimony press release ( UAMY ): FY GAAP EPS of -$0.04 misses by $0.01 . Revenue of $39.26M (+162.8% Y/Y) beats by $0.08M . Today the Company is reiterating its previously provided 2026 gross revenue financial guidance of: 2026 Gross Revenues - $125 Million More on United States Antimony United States Antimony: Plenty Of Growth Ahead If Management Can Execute United States Antimony: ...
United States Antimony press release ( UAMY ): FY GAAP EPS of -$0.04 misses by $0.01 . Revenue of $39.26M (+162.8% Y/Y) beats by $0.08M . Today the Company is reiterating its previously provided 2026 gross revenue financial guidance of: 2026 Gross Revenues - $125 Million More on United States Antimony United States Antimony: Plenty Of Growth Ahead If Management Can Execute United States Antimony: From Obscure Micro-Cap To Strategic U.S. Antimony Supplier United States Antimony Corporation: Buy Solid Growth At A Discount U.S. Antimony wins $27M government contract for critical minerals US agencies develop critical minerals price floor to break China dependence, Bloomberg reports
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Texas Instruments (TXN) is back in the spotlight after unveiling an 800V direct current power architecture for next generation AI data centers, developed with NVIDIA’s 800 VDC reference design. See our latest analysis for Texas ...
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Texas Instruments (TXN) is back in the spotlight after unveiling an 800V direct current power architecture for next generation AI data centers, developed with NVIDIA’s 800 VDC reference design. See our latest analysis for Texas Instruments. Despite the AI data center and edge AI announcements, Texas Instruments’ recent 1 day share price return of a 1.89% decline and 30 day share price return of a 15.64% decline contrast with its 1 year total shareholder return of 8.29%. This suggests that longer term momentum has held up better than the latest pullback. If this AI and power infrastructure theme interests you, it may be a good time to widen your watchlist with other potential beneficiaries using our AI infrastructure stocks screener, starting with 34 AI infrastructure stocks. Texas Instruments now trades around US$190.78 after a 15.64% 30 day decline, despite a 1 year total return of 8.29% and annual revenue and net income growth. Is this pullback an opening, or is the AI upside already in the price? Most Popular Narrative: 39.3% Undervalued Texas Instruments’ last close of $190.78 sits well below the narrative fair value of $314.44, which frames the current pullback in a very different light. Texas Instruments is in the midst of a multiyear capacity-expansion cycle that is temporarily suppressing free cash flow but materially enhancing the company’s long-term competitive position. The buildout of U.S.-based 300mm analog manufacturing is expected to structurally improve cost efficiency, support higher gross margins, and increase supply-chain resilience. As these assets ramp and utilization normalizes, TXN should regain its historical free-cash-flow profile, supported by diversified end-market exposure across industrial, automotive, aerospace/defense, and energy infrastructure. Read the complete nar...
– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan to submit NDA for envudeucitinib in PsO in 2H 2026 – – Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 20...
– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan to submit NDA for envudeucitinib in PsO in 2H 2026 – – Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) anticipated 3Q 2026 – – Presentation of additional Phase 3 ONWARD1 and ONWARD2 data at AAD 2026 – – Completed an upsized public offering raising $345.1 million in gross proceeds in Jan 2026 – SOUTH SAN FRANCISCO, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the year ended December 31, 2025, and highlighted recent achievements and upcoming milestones. “Alumis concluded a pivotal year marked by strong execution and the Phase 3 clinical validation of envudeucitinib in moderate-to-severe plaque psoriasis, underscoring the promise of TYK2 inhibition and envudeucitinib’s highly differentiated clinical profile,” said Martin Babler, President and Chief Executive Officer of Alumis. “By maximally inhibiting TYK2 to block both IL-23 and IL-17 pathways, envudeucitinib delivered comprehensive disease control with rapid onset of action, high rates of skin clearance, and meaningful symptom improvements in our Phase 3 ONWARD program that reinforce our conviction in envudeucitinib’s potential to transform the psoriasis treatment landscape. We look forward to our clinical topline readout for our potentially pivotal LUMUS Phase 2b trial in SLE, anticipated in the third quarter of this year.” Babler added, “Importantly, the results of both psoriasis and SLE will potentially unlock envudeucitinib’s pipeline‑in‑a‑pill’ opportunity to leverage maximal TYK2 inhibition across multiple immune‑mediated diseases. Alumis is evaluating add...
Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026,...
Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the “Company”), a bioelectronic technology company, today announced full year 2025 financial results. Reported record full year of 2025 revenue of $32.0 million, an increase of approximately 27% over full year of 2024. Cash, cash equivalents, and marketable securities (“Total Cash”) of $11.6 million at December 31, 2025. Full year 2026 revenue guidance of approximately 30% annual growth. Announced Chief Executive Officer, Dan Goldberger will retire effective April 1, 2026, and Joshua Lev will be taking on the role of interim President and Chief Financial Officer. Hired Michael Fox as Chief Operating Officer, strengthening the sales management team through his strong track record of driving significant revenue growth across the VA system and other key channels. Full Year 2025 Financial Results and 2026 Select Guidance For the year ended December 31, 2025, electroCore reported net sales of $32.0 million compared to $25.2 million during the same period in 2024, which represents an approximate 27% increase over the prior year. The increase of $6.8 million is primarily due to an increase in net sales of prescription gammaCoreTM and Quell® Fibromyalgia in the United States and TruvagaTM handsets in the general wellness channel. (in thousands) Full year ended December 31, Channel: 2025 2024 % Change United States – Rx $ 24,073 $ 19,307 25 % TAC-STIM 422 1,197 -65 % Outside the United States 1,892 1,785 6 % In-License / Other 96 82 17 % General Wellness 5,549 2,811 9...
Full Year Net Sales of $161.7 million including Proprietary Brand Sales of $44.0 million Full Year Proprietary Brand Penetration Increased to 32.8% up from 24.2% in the prior year Full Year GAAP Net Loss Improved by $25.5 million; Adjusted EBITDA Improved by $8.5 million $46.1 million of Cash and Marketable Securities and no debt Board Authorizes $10 Million Share Repurchase Program 2026 Outlook: ...
Full Year Net Sales of $161.7 million including Proprietary Brand Sales of $44.0 million Full Year Proprietary Brand Penetration Increased to 32.8% up from 24.2% in the prior year Full Year GAAP Net Loss Improved by $25.5 million; Adjusted EBITDA Improved by $8.5 million $46.1 million of Cash and Marketable Securities and no debt Board Authorizes $10 Million Share Repurchase Program 2026 Outlook: Revenue of $162 million to $168 million and Breakeven Adjusted EBITDA(1) DENVER, March 19, 2026 (GLOBE NEWSWIRE) -- GrowGeneration Corp. (NASDAQ: GRWG), (“GrowGeneration,” “GrowGen” or the “Company”), one of the nation’s largest suppliers of specialty products for controlled environment agriculture (CEA), commercial cultivation, and garden centers, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Summary(1) Net sales of $37.8 million, compared to prior year net sales of $37.4 million, an improvement of 1.0%; Proprietary brand sales as a percentage of Cultivation and Gardening net sales increased to 35.8%, compared to 30.4% in the prior year; Gross profit margin of 24.1%, compared to 16.4% in the prior year; Store and other operating expenses declined approximately 26.8% to $6.8 million, compared to $9.3 million for the same period in the prior year; Total operating expenses decreased $13.3 million, or 44.4%, to $16.7 million in the fourth quarter of 2025, compared to $30.1 million in the prior year; Net loss improved to $7.4 million, compared to a net loss of $23.3 million in the prior year which includes non-cash impairments; and Adjusted EBITDA(3) loss of $2.0 million compared to a loss of $8.1 million in the prior year. Full Year 2025 Summary(2) Net sales of $161.7 million, compared to $188.9 million in the prior year, reflecting retail store consolidations in 2024 and 2025. Proprietary brand sales as a percentage of Cultivation and Gardening net sales increased to 32.8%, compared to 24.2% in the prior ye...
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 –
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 –
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –
CULVER CITY, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 and Recent Operational Highlights ARK Franchise Updates: ARK: Survival Evolv...
CULVER CITY, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 and Recent Operational Highlights ARK Franchise Updates: ARK: Survival Evolved (“ASE”): Units sold were approximately 579,248 for the fourth quarter 2025 During the fourth quarter of 2025, average daily active users (“DAU”) was 105,468 and peak DAU was 137,404 ARK: Survival Ascended (“ASA”): Units sold were approximately 691,872 for the fourth quarter 2025 During the fourth quarter of 2025, average DAU was 91,123 and peak DAU was 147,572 Launched ARK Lost Colony DLC Launched 'ARK x Teenage Mutant Ninja Turtles' Cosmetic Pack in collaboration with Look North World ARK: Ultimate Mobile Edition (“ARK Mobile”): Surpassed 10 million downloads as of December 31, 2025 During the fourth quarter of 2025, average DAU was 129,861 2026 / 2027 ASA Content Roadmap 2026 ARK World Creator (scheduled for May 2026) ARK Bob’s True Tales – Tides of Fortune (scheduled for June 2026) ARK Genesis Part 1 (ASA remake) ARK Survival of the Fittest (“SOTF”) ARK Dragontopia (scheduled for December 2026) 2027 ARK Atlantis ARK Bob’s True Tales – Galaxy Wars ARK Legacy of Santiago Game Portfolio Updates: 2026 Games Developers Conference (“GDC”) Introduced PixARK Worlds, a new title in development that features revolutionary user-generated content designed to expand the ARK universe onto the Nintendo Switch 2 Revealed event-exclusive trailer for upcoming AAA title For The Stars Unveiled new indie title, Gobby Gang Bellwright surpassed 1 million downloads on Steam Early Access, announced console port plans to Xbox and PlayStation, and launched the Maiden Voyage update. Following the launch of the update, the title achieved its highest Steam concurrent user peak of the year and sold...
Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 million Launched DESMODA™, the first and only FDA-approved desmopressin oral solution Licensed U.S. rights to Orphan Drug HEMANGEOL ® ; expected to be accretive to...
Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 million Launched DESMODA™, the first and only FDA-approved desmopressin oral solution Licensed U.S. rights to Orphan Drug HEMANGEOL ® ; expected to be accretive to 2026 earnings ; expected to be accretive to 2026 earnings Company expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30% Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2025. “It was another phenomenal quarter for Eton with meaningful contributions from key products across our portfolio including INCRELEX, ALKINDI SPRINKLE, KHINDIVI, and GALZIN. The strong fourth quarter helped us cap off a transformational 2025. During the year we launched three major products, INCRELEX, GALZIN, and KHINDIVI, and delivered $80 million in total revenue, more than doubling our 2024 revenue,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “The recent FDA approval of DESMODA and the acquisition of HEMANGEOL have further accelerated our 2026 growth trajectory. DESMODA’s approval was highly anticipated by the endocrinology community, and the product received a very strong reception in its first week of launch. Our commercial team is fired up and fully mobilized, executing on the launch plan. Our entire team is also hard at work on the integration of HEMANGEOL and eager for our scheduled May 1st relaunch. Both of these products will be key growth contributors in 2026 and beyond. In addition, this year is poised to be our most active year yet on the clin...